The National Institutes of Health (NIH) launched the Trial Innovation Network (TIN) in 2017 to help researchers carry out multicenter clinical trials better, faster and more cost-efficiently, and to create a national laboratory to study, understand and innovate the process of conducting clinical trials.

The ConduITS Institutes for Translational Sciences at Mount Sinai has established a local TIN Hub Liaison Team (THLT) to assist ISMMS investigators to better understand and utilize the TIN.

The ISMMS TIN Hub Liaison Team also provides consultations for individuals requiring multi-site support to assist in determining if we have the resources internally or if investigators should use the TIN.

The TIN offers guidance for multi-center studies like navigation of the single IRB process, input on protocol development, master contracting agreements, quality by design approaches, and a focus on evidence-based strategies to recruitment and patient engagement.. TIN offers additional services besides sIRB and the initial consultation.  Here is a full list. – Initial Consultation and Resources

 Characteristics of ideal TIN proposals

  • Multi-center study design (three or more institutions)
  • Willingness to partner with the TIN through the lifecycle of the project
  • An innovative operational approach to improve quality, efficiency, or cost of clinical research
  • At least 60 days allotted for consultation prior to planned grant submission with substantial project development
  • All populations affected by the health condition being studied, including women, racial/ethnic minorities and children
  • The ability to provide academic evidence to improve clinical trial designs, conduct, and reportability.

ConduITS is supported by NCATS of the NIH’s CTSA Program. Any use of CTSA-supported resources requires citation of grant number UL1TR001433 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required.